valproic acid has been researched along with Schizophrenia in 188 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to assess the efficacy of omega-3 fatty acids on metabolic and inflammatory indices in patients with schizophrenia who were taking clozapine and sodium valproate." | 9.27 | Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate. ( Akhavanrezayat, A; Amlashi, SV; Behdani, F; Ferns, GA; Ghayour-Mobarhan, M; Hebrani, P; Roudbaraki, SN; Saberi-Karimian, M; Tayefi, M, 2018) |
| "The objective of this study was to evaluate the efficacy and safety of divalproex sodium extended release (divalproex ER) vs placebo in combination with olanzapine or risperidone for the treatment of acute exacerbations of schizophrenia." | 9.14 | Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. ( Abi-Saab, W; Baker, J; Casey, DE; Daniel, DG; Greco, N; Kane, JM; Redden, L; Saltarelli, M; Tamminga, C; Tran-Johnson, T; Wozniak, P, 2009) |
| "Augmenting antipsychotics with the mood stabilizers of lamotrigine or divalproex sodium for most partially responsive patients with chronic schizophrenia did not seem to be a useful treatment strategy for improving the residual symptoms." | 9.14 | A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. ( Bosch, J; Casey, DE; Glick, ID, 2009) |
| "While these preliminary results need to be tested against tenacious monotherapy or polypharmacy involving clozapine, augmenting atypical antipsychotics with valproic acid can be useful for very severe schizophrenia." | 9.14 | Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. ( Kashima, H; Nakajima, S; Nomura, K; Suzuki, T; Takeuchi, H; Tanabe, A; Uchida, H; Watanabe, K; Yagi, G, 2009) |
| "The objective of the study was to compare the antiaggressive efficacy of risperidone monotherapy versus risperidone plus valproate in patients with schizophrenia." | 9.12 | Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. ( Citrome, L; Czobor, P; Nolan, KA; Shope, CB; Volavka, J, 2007) |
| "This study compared the specific antihostility effects of atypical antipsychotic monotherapy (olanzapine or risperidone) with that of combination treatment with divalproex sodium among patients with schizophrenia experiencing an acute psychotic episode." | 9.11 | Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. ( Casey, DE; Citrome, L; Daniel, DG; Kochan, LD; Tracy, KA; Wozniak, P, 2004) |
| "The goal of this 5-year naturalistic study of patients treated with clozapine was to examine the incidence of treatment-emergent diabetes mellitus in relation to other factors, including weight gain, lipid abnormalities, age, clozapine dose, and treatment with valproate." | 9.09 | Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. ( Cagliero, E; Goff, DC; Gray, C; Hayden, DL; Henderson, DC; Nasrallah, RA; Schoenfeld, DA, 2000) |
| "Objectives: Clozapine-induced myocarditis may be a hypersensitivity reaction due to titration that was too rapid for a patient's clozapine metabolism." | 8.12 | Four cases of myocarditis in US hospitals possibly associated with clozapine poor metabolism and a comparison with prior published cases. ( Coleman, JK; Cotes, RO; De Leon, J; Goldsmith, DR; Koenig, M; McCollum, B; Shelton, C; Spivey, JK, 2022) |
| "The combination of valproic acid (VPA) and clozapine (CLZ) is regularly prescribed for augmentation therapy in treatment resistant schizophrenia." | 8.12 | Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: Does UGT polymorphism affect these drug interactions? ( Cirujeda, C; Concha, J; García, CB; Padilla, PP; Ribate, MP; Sangüesa, E, 2022) |
| "Clozapine, atypical antipsychotic drug, is widely used in patients with schizophrenia, for whom previous therapy was inadequate or not tolerated." | 7.91 | Clozapine-induced myocarditis during co-administration of valproate: A case report. ( Jahołkowski, P; Kowalski, M; Niewiadomska, J; Świtaj, P; Wciórka, J, 2019) |
| "Certain patients with treatment-refractory schizophrenia may be rechallenged with clozapine following previous neutropenia." | 7.81 | Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis. ( Gaughran, F; Gee, S; MacCabe, JH; Meyer, N; Mijovic, A; Shergill, S; Taylor, D; Whiskey, E, 2015) |
| "Fixed oral doses of clozapine produce up to 45-fold interindividual variability among its serum levels in patients with treatment-resistant schizophrenia." | 7.79 | Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. ( Jacob, KS; Jacob, M; Kuruvilla, A; Poonkuzhali, B; Rajkumar, AP, 2013) |
| "Despite the implementation of cardiac monitoring guidelines, clozapine-induced myocarditis continues to cause deaths in Australia, and the risk is a barrier to prescription of this effective drug for the treatment of schizophrenia." | 7.78 | Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. ( Fitzgerald, PB; McNeil, JJ; Ronaldson, KJ; Taylor, AJ; Topliss, DJ; Wolfe, R, 2012) |
| "There are multiple genetic links between schizophrenia and a deficit of proline dehydrogenase (PRODH) enzyme activity." | 7.77 | Evidence for association of hyperprolinemia with schizophrenia and a measure of clinical outcome. ( Baraldi, AN; Bart, CP; Clelland, CL; Clelland, JD; Nadrich, RH; Panek, LJ; Pappas, CA; Read, LL, 2011) |
| "Valproic acid (VPA) has been suggested as a potential adjunct therapy in schizophrenia for the treatment of clinical symptoms and cognitive deficits." | 7.77 | Effects of adjunct valproic acid on clinical symptoms and saccadic eye movements in schizophrenia. ( Babin, SL; Larrison, AL; Patel, SS; Sereno, AB; Wassef, AA; Xing, Y, 2011) |
| "To determine the incidence, characteristics, and predictors of clozapine-induced fever in a sample of patients in a local psychiatric unit." | 7.74 | The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong. ( Chan, WF; Chung, KF; Lai-wah Dunn, E; Pui-yin Chung, J; Shiu-yin Chong, C; Wai-nang Tang, O, 2008) |
| "This retrospective study examined adjunct divalproex (N = 15) or lithium (N = 9) in treatment-resistant schizophrenia patients added to clozapine and compared to clozapine monotherapy (N = 25)." | 7.73 | Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. ( Conley, RR; Feldman, S; Kelly, DL; McMahon, RP; Richardson, CM; Yu, Y, 2006) |
| "The purpose of the present paper was to remind physicians that hypothermia is a possible side-effect of combining zotepine, valproate,and benzodiazepine." | 7.72 | Two case studies of hypothermia induced by an increased dosage of zotepine in a combination therapy. ( Chen, KC; Chen, PS; Yang, MJ; Yang, YK; Yeh, TL, 2003) |
| "To determine whether there is a pharmacokinetic drug interaction between quetiapine fumarate and divalproex sodium." | 6.73 | Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. ( Davis, PC; DeVane, CL; Ennis, DJ; Figueroa, C; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2007) |
| " Treatment with divalproex in combination with an atypical antipsychotic agent resulted in earlier improvements in a range of psychotic symptoms among acutely hospitalized patients with schizophrenia." | 6.71 | Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. ( Casey, DE; Daniel, DG; Sommerville, KW; Tracy, KA; Wassef, AA; Wozniak, P, 2003) |
| "Its usefulness in schizophrenia has yet to be adequately assessed." | 6.70 | Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. ( Hafiz, NG; Hampton, D; Molloy, M; Wassef, AA, 2001) |
| "Valproic acid (VPA) is a commonly used antiepileptic drug (AED)." | 6.61 | Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. ( Kashyap, A; Rashid, M; Undela, K, 2019) |
| "Schizophrenia is a neurodevelopmental disorder with onset early in adulthood." | 5.38 | Prophylactic valproic acid treatment prevents schizophrenia-related behaviour in Disc1-L100P mutant mice. ( Berger, T; Boutros, PC; Haque, FN; Lipina, TV; Mak, TW; McGirr, A; Roder, JC; Wong, AH, 2012) |
| "Topiramate is an antiepileptic drug, recently also used in the treatment of psychiatric diseases." | 5.33 | Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. ( Gaudreau, PO; Gobbi, G; Leblanc, N, 2006) |
| "Valproic acid is a carboxylic acid used for the treatment of both seizure and mood disorders." | 5.32 | Valproic acid-induced eosinophilic pleural effusion. ( Federman, DG; Kravetz, JD, 2003) |
| " We aimed to assess the efficacy of omega-3 fatty acids on metabolic and inflammatory indices in patients with schizophrenia who were taking clozapine and sodium valproate." | 5.27 | Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate. ( Akhavanrezayat, A; Amlashi, SV; Behdani, F; Ferns, GA; Ghayour-Mobarhan, M; Hebrani, P; Roudbaraki, SN; Saberi-Karimian, M; Tayefi, M, 2018) |
| "This study compares the metabolic effects of olanzapine and risperidone in a prospective, randomized, open-label trial in 160 patients with DSM-IV-TR schizophrenia, schizoaffective disorder, or bipolar disorder after 1, 3, 6, and 12 months' treatment." | 5.15 | A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. ( Bobo, WV; Bonaccorso, S; Chen, Y; Jayathilake, K; Meltzer, HY, 2011) |
| "The objective of this study was to evaluate the efficacy and safety of divalproex sodium extended release (divalproex ER) vs placebo in combination with olanzapine or risperidone for the treatment of acute exacerbations of schizophrenia." | 5.14 | Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. ( Abi-Saab, W; Baker, J; Casey, DE; Daniel, DG; Greco, N; Kane, JM; Redden, L; Saltarelli, M; Tamminga, C; Tran-Johnson, T; Wozniak, P, 2009) |
| "Augmenting antipsychotics with the mood stabilizers of lamotrigine or divalproex sodium for most partially responsive patients with chronic schizophrenia did not seem to be a useful treatment strategy for improving the residual symptoms." | 5.14 | A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. ( Bosch, J; Casey, DE; Glick, ID, 2009) |
| "While these preliminary results need to be tested against tenacious monotherapy or polypharmacy involving clozapine, augmenting atypical antipsychotics with valproic acid can be useful for very severe schizophrenia." | 5.14 | Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. ( Kashima, H; Nakajima, S; Nomura, K; Suzuki, T; Takeuchi, H; Tanabe, A; Uchida, H; Watanabe, K; Yagi, G, 2009) |
| "The objective of the study was to compare the antiaggressive efficacy of risperidone monotherapy versus risperidone plus valproate in patients with schizophrenia." | 5.12 | Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. ( Citrome, L; Czobor, P; Nolan, KA; Shope, CB; Volavka, J, 2007) |
| " We examine the cellular distribution and activation of PKC and receptor-G protein coupling in blood platelets from normal controls, patients with BD mania or schizophrenia during treatment-free state, and after lithium or valproic acid administration." | 5.11 | Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. ( Friedman, E; Hahn, CG; Koneru, R; Levinson, DF; Wang, HY, 2005) |
| "This study compared the specific antihostility effects of atypical antipsychotic monotherapy (olanzapine or risperidone) with that of combination treatment with divalproex sodium among patients with schizophrenia experiencing an acute psychotic episode." | 5.11 | Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. ( Casey, DE; Citrome, L; Daniel, DG; Kochan, LD; Tracy, KA; Wozniak, P, 2004) |
| ", who received at least 6 weeks of add-on olanzapine treatment for psychotic mood disorders (schizoaffective disorders [bipolar and depressive type], bipolar disorders [I, II, and NOS], and major depressive disorder)." | 5.09 | Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. ( Grace, JJ; Narendran, R; Pato, MT; Pristach, CA; Valenti, AM; Young, CM, 2001) |
| "The goal of this 5-year naturalistic study of patients treated with clozapine was to examine the incidence of treatment-emergent diabetes mellitus in relation to other factors, including weight gain, lipid abnormalities, age, clozapine dose, and treatment with valproate." | 5.09 | Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. ( Cagliero, E; Goff, DC; Gray, C; Hayden, DL; Henderson, DC; Nasrallah, RA; Schoenfeld, DA, 2000) |
| "The hypothesis of a gamma-aminobutyric acid (GABA) involvement in the pathophysiology of schizophrenia has been recently proposed but not confirmed." | 5.06 | Growth hormone response to sodium valproate in chronic schizophrenia. ( Iovino, M; Maj, M; Monteleone, P; Steardo, L, 1986) |
| "Valproate (the active moiety of both valproic acid and divalproex sodium) is commonly used as an adjunctive agent for the treatment of schizophrenia." | 4.82 | Schizophrenia and valproate. ( Citrome, L, 2003) |
| "This article is based upon a review of relevant literature on treatment with the mood stabilizers lithium, carbamazepine, valproate and lamotrigine in patients with schizophrenia." | 4.82 | [Are mood stabilizers beneficial in the treatment of schizophrenia?]. ( Berle, JØ; Spigset, O, 2005) |
| "The atypical antipsychotics risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole have become first-line treatment for schizophrenia because they reduce the positive symptoms of psychosis but do not have a high incidence of extrapyramidal symptoms." | 4.82 | A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. ( Grady, MM; Stahl, SM, 2004) |
| "A role for gamma-aminobutyric acid (GABA) in the pathophysiology of schizophrenia was first suggested by Eugene Roberts in 1972." | 4.76 | The interaction between GABA and dopamine: implications for schizophrenia. ( Garbutt, JC; van Kammen, DP, 1983) |
| " We report the case of a young man with a first episode schizophrenia who experienced thrombocytopenic purpura following the administration of quetiapine co-prescribed with valproic acid." | 4.31 | Quetiapine-associated thrombocytopenic purpura in a young man with a first episode schizophrenia. ( Cheour, M; Cherif, W; Fekih-Romdhane, F; Jenhani, R, 2023) |
| "Objectives: Clozapine-induced myocarditis may be a hypersensitivity reaction due to titration that was too rapid for a patient's clozapine metabolism." | 4.12 | Four cases of myocarditis in US hospitals possibly associated with clozapine poor metabolism and a comparison with prior published cases. ( Coleman, JK; Cotes, RO; De Leon, J; Goldsmith, DR; Koenig, M; McCollum, B; Shelton, C; Spivey, JK, 2022) |
| "The combination of valproic acid (VPA) and clozapine (CLZ) is regularly prescribed for augmentation therapy in treatment resistant schizophrenia." | 4.12 | Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: Does UGT polymorphism affect these drug interactions? ( Cirujeda, C; Concha, J; García, CB; Padilla, PP; Ribate, MP; Sangüesa, E, 2022) |
| "Clozapine (CLZ) is a gold-standard antipsychotic against treatment-refractory schizophrenia, but is one of the most toxic antipsychotic agents." | 3.96 | Activation of Astroglial Connexin is Involved in Concentration-Dependent Double-Edged Sword Clinical Action of Clozapine. ( Fukuyama, K; Murata, M; Okada, M; Okubo, R; Shiroyama, T, 2020) |
| "Clozapine, atypical antipsychotic drug, is widely used in patients with schizophrenia, for whom previous therapy was inadequate or not tolerated." | 3.91 | Clozapine-induced myocarditis during co-administration of valproate: A case report. ( Jahołkowski, P; Kowalski, M; Niewiadomska, J; Świtaj, P; Wciórka, J, 2019) |
| "This retrospective observational study was performed to investigate electroencephalogram abnormalities in clozapine-treated patients with refractory schizophrenia or bipolar disorder." | 3.91 | Association between electroencephalogram changes and plasma clozapine levels in clozapine-treated patients. ( Chung, IW; Jeong, SH; Jeong, SW; Jung, HY; Kim, HS; Kim, KK; Kim, SH; Kim, YS; Youn, T, 2019) |
| "We found increased risks of cataract development in long-term users of lithium, lithium combined with other MS and valproic acid combined with other MS for more than two years among patients with BD and schizophrenia." | 3.88 | Associations between use of mood stabilizers and risk of cataract: A population-based nested case-control study. ( Chou, PH; Chu, CS; Lan, TH; Lin, CH, 2018) |
| "We describe a case of clozapine toxicity in a patient with schizophrenia treated with the combination of clozapine, valproate and haloperidol." | 3.88 | Clozapine toxicity in a CYP2D6 poor metaboliser: Additive effects of haloperidol and valproate on clozapine metabolism. ( Chen, RYY; Reznik, R; Stanford, P, 2018) |
| "Valproic acid is often used in psychiatry to treat schizophrenia and other conditions outside of indication ("off-label")." | 3.81 | [Use of valproic acid in long stay units of psychiatry]. ( Chillerón-Cuenca, R; Esplá-González, S; Hernández-Pérez, P; Herraiz-Robles, P; Martínez-Lazcano, MT; Pol-Yanguas, E, 2015) |
| "Clozapine monotherapy is clearly the optimal medication in medication refractory schizophrenia and it is possible to maximise its use." | 3.81 | Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia. ( Joyce, DW; Mateos Fernandez, MJ; Sarkar, SN; Shergill, SS; Tracy, DK, 2015) |
| "Certain patients with treatment-refractory schizophrenia may be rechallenged with clozapine following previous neutropenia." | 3.81 | Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis. ( Gaughran, F; Gee, S; MacCabe, JH; Meyer, N; Mijovic, A; Shergill, S; Taylor, D; Whiskey, E, 2015) |
| "Fixed oral doses of clozapine produce up to 45-fold interindividual variability among its serum levels in patients with treatment-resistant schizophrenia." | 3.79 | Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. ( Jacob, KS; Jacob, M; Kuruvilla, A; Poonkuzhali, B; Rajkumar, AP, 2013) |
| "Despite the implementation of cardiac monitoring guidelines, clozapine-induced myocarditis continues to cause deaths in Australia, and the risk is a barrier to prescription of this effective drug for the treatment of schizophrenia." | 3.78 | Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. ( Fitzgerald, PB; McNeil, JJ; Ronaldson, KJ; Taylor, AJ; Topliss, DJ; Wolfe, R, 2012) |
| "Valproic acid (VPA) has been suggested as a potential adjunct therapy in schizophrenia for the treatment of clinical symptoms and cognitive deficits." | 3.77 | Effects of adjunct valproic acid on clinical symptoms and saccadic eye movements in schizophrenia. ( Babin, SL; Larrison, AL; Patel, SS; Sereno, AB; Wassef, AA; Xing, Y, 2011) |
| "There are multiple genetic links between schizophrenia and a deficit of proline dehydrogenase (PRODH) enzyme activity." | 3.77 | Evidence for association of hyperprolinemia with schizophrenia and a measure of clinical outcome. ( Baraldi, AN; Bart, CP; Clelland, CL; Clelland, JD; Nadrich, RH; Panek, LJ; Pappas, CA; Read, LL, 2011) |
| "This study investigated the effects of three AEDs (carbamazepine, oxcarbazepine, and valproic acid) on nicotine and nicotine metabolite levels in 149 smokers with schizophrenia and bipolar disorder who participated in an afternoon blood draw for nicotine, cotinine, and 3'-hydroxycotinine (3HC)." | 3.76 | Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness. ( Benowitz, NL; Gandhi, KK; Williams, JM, 2010) |
| "Recent advances in schizophrenia (SZ) research indicate that the telencephalic gamma-aminobutyric acid (GABA)ergic neurotransmission deficit associated with this psychiatric disorder probably is mediated by the hypermethylation of the glutamic acid decarboxylase 67 (GAD(67)), reelin and other GABAergic promoters." | 3.75 | Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. ( Costa, E; Dong, E; Grayson, DR; Guidotti, A; Kundakovic, M; Satta, R, 2009) |
| "To determine the incidence, characteristics, and predictors of clozapine-induced fever in a sample of patients in a local psychiatric unit." | 3.74 | The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong. ( Chan, WF; Chung, KF; Lai-wah Dunn, E; Pui-yin Chung, J; Shiu-yin Chong, C; Wai-nang Tang, O, 2008) |
| "This retrospective study examined adjunct divalproex (N = 15) or lithium (N = 9) in treatment-resistant schizophrenia patients added to clozapine and compared to clozapine monotherapy (N = 25)." | 3.73 | Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. ( Conley, RR; Feldman, S; Kelly, DL; McMahon, RP; Richardson, CM; Yu, Y, 2006) |
| "To evaluate clinical efficacy of clozapine in relation with its plasma level in a group of Chinese patients with treatment-resistant schizophrenia." | 3.73 | Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. ( Chan, KT; Choi, WK; Hon-Kee Cheung, H; Lai, J; Leung, SP; Mak, T; Ng, RM; Wai-Kiu Tsang, A; Wong, JO, 2006) |
| "The purpose of the present paper was to remind physicians that hypothermia is a possible side-effect of combining zotepine, valproate,and benzodiazepine." | 3.72 | Two case studies of hypothermia induced by an increased dosage of zotepine in a combination therapy. ( Chen, KC; Chen, PS; Yang, MJ; Yang, YK; Yeh, TL, 2003) |
| "The study describes changes over time in the adjunctive use of valproate and other mood stabilizers-lithium, carbamazepine, and gabapentin--among hospitalized psychiatric patients with a diagnosis of schizophrenia." | 3.70 | Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. ( Allingham, B; Citrome, L; Levine, J, 2000) |
| "A 25-year-old white woman with a history of multiple suicide attempts and schizophrenia presented after ingesting an unknown amount of valproic acid." | 3.70 | High-flux hemodialysis without hemoperfusion is effective in acute valproic acid overdose. ( Constantiner, M; Kane, SL; Meinecke, CD; Sedor, JR; Staubus, AE, 2000) |
| "An experimental and clinico-pharmacological study of sodium valproate, a GABA-ergic drug, was conducted to elucidate the role of gamma-aminobutyric acid in the mechanisms responsible for affective disturbances, in particular for anxiety." | 3.67 | [Anxiolytic action of sodium valproate (possible role of gamma-aminobutyric acid in affective disorders)]. ( Aleksandrovskiĭ, IuA; Kharlamov, AN; Neznamov, GG; Poiurovskiĭ, MV; Raevskiĭ, KS, 1985) |
| "To determine whether there is a pharmacokinetic drug interaction between quetiapine fumarate and divalproex sodium." | 2.73 | Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. ( Davis, PC; DeVane, CL; Ennis, DJ; Figueroa, C; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2007) |
| " Treatment with divalproex in combination with an atypical antipsychotic agent resulted in earlier improvements in a range of psychotic symptoms among acutely hospitalized patients with schizophrenia." | 2.71 | Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. ( Casey, DE; Daniel, DG; Sommerville, KW; Tracy, KA; Wassef, AA; Wozniak, P, 2003) |
| " A nonsignificant increase in the rate of adverse events was noted in the intravenous group." | 2.71 | Acute antimanic efficacy and safety of intravenous valproate loading therapy: an open-label study. ( Akhtar, S; Basu, S; Duggal, H; Gupta, S; Jagadheesan, K; Nizamie, SH; Ranjan, S; Sandil, R, 2003) |
| " Measured at baseline and end point were the Brief Psychiatric Rating Scale and the Udvalg for Kliniske Undersogelser Side Effect Rating Scale." | 2.71 | A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia. ( Citrome, L; Dinakar, H; Roy, B; Tremeau, F; Wynn, PS, 2004) |
| "Its usefulness in schizophrenia has yet to be adequately assessed." | 2.70 | Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. ( Hafiz, NG; Hampton, D; Molloy, M; Wassef, AA, 2001) |
| "With valproic acid, there was a minor increase in total clozapine metabolites, which was even less with dose correction." | 2.67 | Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. ( Baldessarini, RJ; Centorrino, F; Flood, JG; Frankenburg, FR; Kando, J; Puopolo, PR; Volpicelli, SA, 1994) |
| "Valproic acid (VPA) is a commonly used antiepileptic drug (AED)." | 2.61 | Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. ( Kashyap, A; Rashid, M; Undela, K, 2019) |
| "valproate alone is an effective treatment for schizophrenia and schizoaffective psychoses; and2." | 2.53 | Valproate for schizophrenia. ( Helfer, B; Leucht, S; Li, C; Wang, Y; Xia, J, 2016) |
| "A diagnosis of neuroleptic malignant syndrome was made and the patient continued to receive aggressive supportive care." | 2.41 | Neuroleptic malignant syndrome and severe thrombocytopenia: case report and literature review. ( Ahmed, W; Ghani, SO; Marco, LA, 2000) |
| "Sydenham's chorea is a symptom of rheumatic fever and results from an autoimmune attack on the CNS." | 2.39 | Neuropsychiatric aspects of Sydenham's chorea: a comprehensive review. ( Moore, DP, 1996) |
| "Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function." | 2.36 | Pharmacology of GABA. ( Meldrum, B, 1982) |
| "Valproic acid is an anticonvulsant, which is also widely used for treating psychiatric disorders." | 1.62 | Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia. ( Ju, X; Li, J; Liu, J; Shi, J; Song, M; Wang, C; Wang, S; Yan, P, 2021) |
| "Valproic acid was related to the highest risk." | 1.48 | Severe hair loss associated with psychotropic drugs in psychiatric inpatients-Data from an observational pharmacovigilance program in German-speaking countries. ( Bleich, S; Burda, K; Druschky, K; Frieling, H; Grohmann, R; Hillemacher, T; Neyazi, A; Stübner, S; Toto, S, 2018) |
| "People with schizophrenia are at greater risk for cardiovascular disease and their overall mortality rate is elevated compared to the general population." | 1.43 | Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder. ( Greene, CM; Henderson, DC; Jackson, JW; Parnarouskis, L; Ulloa, M; Vincenzi, B, 2016) |
| "Schizophrenia has been considered a devastating clinical syndrome rather than a single disease." | 1.40 | Valproate reverts zinc and potassium imbalance in schizophrenia-derived reprogrammed cells. ( Cadilhe, DV; Cardoso, SC; Paulsen, Bda S; Rehen, SK; Stelling, MP, 2014) |
| "Valproic acid was found to have a significant impact on the worsening of BMI from overweight to obesity (P<0." | 1.40 | The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia. ( Ching, HY; Wang, PS; Wu, SL, 2014) |
| "Schizophrenia has been defined as a neurodevelopmental disease that causes changes in the process of thoughts, perceptions, and emotions, usually leading to a mental deterioration and affective blunting." | 1.38 | Altered oxygen metabolism associated to neurogenesis of induced pluripotent stem cells derived from a schizophrenic patient. ( Belmonte-de-Abreu, PS; Bonamino, M; Brentani, H; Castro, NG; Chicaybam, L; de Moraes Maciel, R; dos Santos Souza, C; Drummond, H; Galina, A; Massuda, R; Nascimento Pozzatto, E; Paulsen, Bda S; Rehen, SK; Setti-Perdigão, P; Silva, H; Souza da Silveira, M, 2012) |
| "Schizophrenia is a neurodevelopmental disorder with onset early in adulthood." | 1.38 | Prophylactic valproic acid treatment prevents schizophrenia-related behaviour in Disc1-L100P mutant mice. ( Berger, T; Boutros, PC; Haque, FN; Lipina, TV; Mak, TW; McGirr, A; Roder, JC; Wong, AH, 2012) |
| "As carnitine deficiency is a potentially treatable condition further studies are warranted." | 1.37 | Clinical correlates of low serum carnitine levels in hospitalized psychiatric patients. ( Abramson, RK; Cuturic, M; Hall, AV; Hardin, JW; Moran, RR, 2011) |
| "Prescribing adjunctive mood stabilizers to manage schizophrenia is prevalent, despite the lack of substantial evidence to support the long-term use of this treatment regimen." | 1.34 | The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia. ( Chen, H; Dorfman, JH; Fincham, JE; Kennedy, WK; Martin, BC; Reeves, J, 2007) |
| "Leukopenia and neutropenia are recognised as side effects of antipsychotic medication, notably clozapine." | 1.34 | Leukopenia and neutropenia induced by quetiapine. ( Cowan, C; Oakley, C, 2007) |
| "Topiramate is an antiepileptic drug, recently also used in the treatment of psychiatric diseases." | 1.33 | Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. ( Gaudreau, PO; Gobbi, G; Leblanc, N, 2006) |
| " Coadministration with lithium increased mean Cmax and AUC values of aripiprazole by about 19% and 15%, respectively, whereas the apparent oral clearance decreased by 15%." | 1.33 | Pharmacokinetics of aripiprazole and concomitant lithium and valproate. ( Bark, N; Citrome, L; Josiassen, R; Mallikaarjun, S; Salazar, DE, 2005) |
| "Valproic acid is a carboxylic acid used for the treatment of both seizure and mood disorders." | 1.32 | Valproic acid-induced eosinophilic pleural effusion. ( Federman, DG; Kravetz, JD, 2003) |
| " Four to 5 Cmin were monitored just before the morning valproic acid dose for 3 to 4 days preceding the kinetic study." | 1.27 | The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ( Chiba, K; Iizuka, R; Ishizaki, T; Kobayashi, K; Saito, M, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (11.17) | 18.7374 |
| 1990's | 26 (13.83) | 18.2507 |
| 2000's | 80 (42.55) | 29.6817 |
| 2010's | 49 (26.06) | 24.3611 |
| 2020's | 12 (6.38) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, S | 1 |
| Li, J | 1 |
| Song, M | 1 |
| Yan, P | 1 |
| Ju, X | 1 |
| Liu, J | 1 |
| Wang, C | 1 |
| Shi, J | 1 |
| Fekih-Romdhane, F | 1 |
| Jenhani, R | 1 |
| Cherif, W | 1 |
| Cheour, M | 1 |
| Koenig, M | 1 |
| McCollum, B | 1 |
| Spivey, JK | 1 |
| Coleman, JK | 1 |
| Shelton, C | 1 |
| Cotes, RO | 1 |
| Goldsmith, DR | 1 |
| De Leon, J | 3 |
| Sangüesa, E | 1 |
| Cirujeda, C | 1 |
| Concha, J | 1 |
| Padilla, PP | 1 |
| García, CB | 1 |
| Ribate, MP | 1 |
| Puranen, A | 1 |
| Koponen, M | 1 |
| Lähteenvuo, M | 1 |
| Tanskanen, A | 1 |
| Tiihonen, J | 1 |
| Taipale, H | 1 |
| Tsukahara, M | 1 |
| So, R | 1 |
| Yoshimura, Y | 1 |
| Yamashita, R | 1 |
| Yada, Y | 1 |
| Kodama, M | 1 |
| Nakajima, S | 2 |
| Kishi, Y | 1 |
| Takeda, T | 1 |
| Yamada, N | 1 |
| Takeuchi, H | 3 |
| Ibrahim, I | 1 |
| Tobar, S | 1 |
| Fathi, W | 1 |
| ElSayed, H | 1 |
| Yassein, A | 1 |
| Eissa, A | 1 |
| Elsheshtawy, E | 1 |
| Elboraei, H | 1 |
| Shahda, M | 1 |
| Elwasify, M | 1 |
| Ibrahim, A | 1 |
| Chen, K | 1 |
| Wood, J | 1 |
| Dickerson, F | 1 |
| Yolken, RH | 1 |
| El Chennawi, F | 1 |
| Gur, R | 2 |
| El Bahaey, W | 1 |
| Nimgaonkar, V | 1 |
| Mansour, H | 1 |
| Jahołkowski, P | 1 |
| Niewiadomska, J | 1 |
| Wciórka, J | 1 |
| Kowalski, M | 1 |
| Świtaj, P | 1 |
| Deng, SH | 1 |
| Wang, ZZ | 1 |
| Lu, HY | 1 |
| Li, L | 1 |
| Hu, JQ | 1 |
| Zhu, XQ | 1 |
| Xie, HS | 1 |
| Chen, HZ | 1 |
| Zhang, M | 1 |
| Ni, XJ | 1 |
| Qiu, C | 1 |
| Shang, DW | 1 |
| Wen, YG | 1 |
| Fukuyama, K | 1 |
| Okubo, R | 1 |
| Murata, M | 1 |
| Shiroyama, T | 1 |
| Okada, M | 1 |
| Naguy, A | 1 |
| Andrade, G | 1 |
| Simões do Couto, F | 1 |
| Câmara-Pestana, L | 1 |
| Al-Eitan, LN | 1 |
| Omari, IO | 1 |
| Alkhatib, RQ | 1 |
| Aljamal, HA | 1 |
| Zhao, Y | 1 |
| Wen, SW | 1 |
| Qin, Y | 1 |
| Liu, Y | 1 |
| Gao, Y | 1 |
| Retnakaran, R | 1 |
| Zhang, R | 1 |
| Zhai, D | 1 |
| Seredenina, T | 1 |
| Sorce, S | 1 |
| Herrmann, FR | 1 |
| Ma Mulone, XJ | 1 |
| Plastre, O | 1 |
| Aguzzi, A | 1 |
| Jaquet, V | 1 |
| Krause, KH | 1 |
| Muñoz-Estrada, J | 1 |
| Lora-Castellanos, A | 1 |
| Meza, I | 1 |
| Alarcón Elizalde, S | 1 |
| Benítez-King, G | 1 |
| Chu, CS | 1 |
| Lin, CH | 1 |
| Lan, TH | 1 |
| Chou, PH | 1 |
| Behdani, F | 1 |
| Roudbaraki, SN | 1 |
| Saberi-Karimian, M | 1 |
| Tayefi, M | 1 |
| Hebrani, P | 1 |
| Akhavanrezayat, A | 1 |
| Amlashi, SV | 1 |
| Ferns, GA | 1 |
| Ghayour-Mobarhan, M | 1 |
| Reznik, R | 1 |
| Chen, RYY | 1 |
| Stanford, P | 1 |
| Scruth, E | 1 |
| Druschky, K | 1 |
| Bleich, S | 1 |
| Grohmann, R | 1 |
| Burda, K | 1 |
| Frieling, H | 1 |
| Hillemacher, T | 1 |
| Neyazi, A | 1 |
| Stübner, S | 1 |
| Toto, S | 1 |
| Rashid, M | 1 |
| Kashyap, A | 1 |
| Undela, K | 1 |
| Kim, HS | 1 |
| Youn, T | 1 |
| Kim, SH | 1 |
| Jeong, SH | 1 |
| Jung, HY | 1 |
| Jeong, SW | 1 |
| Kim, KK | 1 |
| Kim, YS | 1 |
| Chung, IW | 1 |
| Fond, G | 1 |
| Macgregor, A | 1 |
| Tamouza, R | 1 |
| Hamdani, N | 1 |
| Meary, A | 1 |
| Leboyer, M | 1 |
| Dubremetz, JF | 1 |
| Wang, PS | 1 |
| Wu, SL | 1 |
| Ching, HY | 1 |
| Ene-Stroescu, V | 1 |
| Nguyen, T | 1 |
| Waiblinger, BE | 1 |
| Paulsen, Bda S | 2 |
| Cardoso, SC | 1 |
| Stelling, MP | 1 |
| Cadilhe, DV | 1 |
| Rehen, SK | 2 |
| Horowitz, E | 1 |
| Bergman, LC | 1 |
| Ashkenazy, C | 1 |
| Moscona-Hurvitz, I | 1 |
| Grinvald-Fogel, H | 1 |
| Magnezi, R | 1 |
| Dubovsky, SL | 1 |
| Daurignac, E | 1 |
| Leonard, KE | 1 |
| De Berardis, D | 1 |
| Campanella, D | 1 |
| Serroni, N | 1 |
| Rapini, G | 1 |
| Olivieri, L | 1 |
| Fornaro, M | 1 |
| Valchera, A | 1 |
| Iasevoli, F | 1 |
| Napoletano, C | 1 |
| Martinotti, G | 1 |
| Giannantonio, MD | 1 |
| Martínez-Lazcano, MT | 1 |
| Esplá-González, S | 1 |
| Herraiz-Robles, P | 1 |
| Hernández-Pérez, P | 1 |
| Chillerón-Cuenca, R | 1 |
| Pol-Yanguas, E | 1 |
| Suzuki, T | 3 |
| Uchida, H | 2 |
| Tsunoda, K | 1 |
| Ishizuki, T | 1 |
| Mimura, M | 1 |
| Tracy, DK | 1 |
| Joyce, DW | 1 |
| Sarkar, SN | 1 |
| Mateos Fernandez, MJ | 1 |
| Shergill, SS | 1 |
| Passeri, E | 1 |
| Wilson, AM | 1 |
| Primerano, A | 1 |
| Kondo, MA | 1 |
| Sengupta, S | 1 |
| Srivastava, R | 1 |
| Koga, M | 1 |
| Obie, C | 1 |
| Zandi, PP | 1 |
| Goes, FS | 1 |
| Valle, D | 1 |
| Rapoport, JL | 1 |
| Sawa, A | 1 |
| Kano, S | 1 |
| Ishizuka, K | 1 |
| Bator, E | 1 |
| Latusz, J | 1 |
| Radaszkiewicz, A | 1 |
| Wędzony, K | 1 |
| Maćkowiak, M | 1 |
| Meyer, N | 1 |
| Gee, S | 1 |
| Whiskey, E | 1 |
| Taylor, D | 1 |
| Mijovic, A | 1 |
| Gaughran, F | 1 |
| Shergill, S | 1 |
| MacCabe, JH | 1 |
| Tseng, PT | 1 |
| Chen, YW | 1 |
| Chung, W | 1 |
| Tu, KY | 1 |
| Wang, HY | 2 |
| Wu, CK | 1 |
| Lin, PY | 1 |
| Kasper, S | 1 |
| Vincenzi, B | 1 |
| Greene, CM | 1 |
| Ulloa, M | 1 |
| Parnarouskis, L | 1 |
| Jackson, JW | 1 |
| Henderson, DC | 2 |
| Lana, F | 1 |
| Martí-Bonany, J | 1 |
| Wang, Y | 1 |
| Xia, J | 1 |
| Helfer, B | 1 |
| Li, C | 2 |
| Leucht, S | 4 |
| Schwarz, C | 1 |
| Volz, A | 1 |
| Casey, DE | 4 |
| Daniel, DG | 3 |
| Tamminga, C | 1 |
| Kane, JM | 1 |
| Tran-Johnson, T | 1 |
| Wozniak, P | 3 |
| Abi-Saab, W | 1 |
| Baker, J | 1 |
| Redden, L | 1 |
| Greco, N | 1 |
| Saltarelli, M | 1 |
| Pui-yin Chung, J | 1 |
| Shiu-yin Chong, C | 1 |
| Chung, KF | 1 |
| Lai-wah Dunn, E | 1 |
| Wai-nang Tang, O | 1 |
| Chan, WF | 1 |
| Guidotti, A | 8 |
| Dong, E | 3 |
| Kundakovic, M | 1 |
| Satta, R | 1 |
| Grayson, DR | 6 |
| Costa, E | 8 |
| Ladds, B | 1 |
| Thomas, P | 1 |
| Mejia, C | 1 |
| Hauser, D | 1 |
| Washizuka, S | 1 |
| Iwamoto, K | 1 |
| Kakiuchi, C | 1 |
| Bundo, M | 1 |
| Kato, T | 1 |
| Gavin, DP | 1 |
| Kartan, S | 2 |
| Chase, K | 2 |
| Jayaraman, S | 1 |
| Sharma, RP | 2 |
| Hurdle, AC | 1 |
| Moss, RD | 1 |
| Nolan, KA | 2 |
| Shope, CB | 2 |
| Citrome, L | 9 |
| Volavka, J | 2 |
| Glick, ID | 1 |
| Bosch, J | 1 |
| Nomura, K | 1 |
| Tanabe, A | 1 |
| Yagi, G | 1 |
| Watanabe, K | 1 |
| Kashima, H | 1 |
| Tueting, P | 3 |
| Davis, JM | 2 |
| Veldic, M | 3 |
| Pibiri, F | 1 |
| Kadriu, B | 1 |
| Cuturic, M | 1 |
| Abramson, RK | 1 |
| Moran, RR | 1 |
| Hardin, JW | 1 |
| Hall, AV | 1 |
| Williams, JM | 1 |
| Gandhi, KK | 1 |
| Benowitz, NL | 1 |
| Ventriglio, A | 1 |
| Vincenti, A | 1 |
| Centorrino, F | 2 |
| Talamo, A | 1 |
| Fitzmaurice, G | 1 |
| Baldessarini, RJ | 2 |
| Feifel, D | 1 |
| Shilling, PD | 1 |
| Melendez, G | 1 |
| Clelland, CL | 1 |
| Read, LL | 1 |
| Baraldi, AN | 1 |
| Bart, CP | 1 |
| Pappas, CA | 1 |
| Panek, LJ | 1 |
| Nadrich, RH | 1 |
| Clelland, JD | 1 |
| Meltzer, HY | 3 |
| Bonaccorso, S | 1 |
| Bobo, WV | 1 |
| Chen, Y | 1 |
| Jayathilake, K | 1 |
| Gazdag, G | 1 |
| Takács, R | 1 |
| Ungvari, GS | 1 |
| van Elst, LT | 1 |
| Schulze-Bonhage, A | 1 |
| Altenmüller, D | 1 |
| Ebert, D | 1 |
| Sonik, P | 1 |
| Hilty, DM | 1 |
| Rossaro, L | 1 |
| Bourgeois, JA | 2 |
| de Moraes Maciel, R | 1 |
| Galina, A | 1 |
| Souza da Silveira, M | 1 |
| dos Santos Souza, C | 1 |
| Drummond, H | 1 |
| Nascimento Pozzatto, E | 1 |
| Silva, H | 1 |
| Chicaybam, L | 1 |
| Massuda, R | 1 |
| Setti-Perdigão, P | 1 |
| Bonamino, M | 1 |
| Belmonte-de-Abreu, PS | 1 |
| Castro, NG | 1 |
| Brentani, H | 1 |
| Hsu, WY | 1 |
| Kuo, SY | 1 |
| Huang, SS | 1 |
| Chang, TG | 1 |
| Chiu, NY | 1 |
| Larrison, AL | 1 |
| Babin, SL | 1 |
| Xing, Y | 1 |
| Patel, SS | 1 |
| Wassef, AA | 6 |
| Sereno, AB | 1 |
| Bowen, DJ | 1 |
| Lucas, NL | 1 |
| Braude, S | 1 |
| Canan, F | 1 |
| Aydinoglu, U | 1 |
| Sinani, G | 1 |
| Ronaldson, KJ | 1 |
| Fitzgerald, PB | 1 |
| Taylor, AJ | 1 |
| Topliss, DJ | 1 |
| Wolfe, R | 1 |
| McNeil, JJ | 1 |
| Rajkumar, AP | 1 |
| Poonkuzhali, B | 1 |
| Kuruvilla, A | 1 |
| Jacob, M | 1 |
| Jacob, KS | 1 |
| Lipina, TV | 1 |
| Haque, FN | 1 |
| McGirr, A | 1 |
| Boutros, PC | 1 |
| Berger, T | 1 |
| Mak, TW | 1 |
| Roder, JC | 1 |
| Wong, AH | 1 |
| Crosby, D | 1 |
| Peterson, J | 1 |
| Carroll, BT | 1 |
| Hasan, A | 1 |
| Mitchell, A | 1 |
| Schneider, A | 1 |
| Halene, T | 1 |
| Akbarian, S | 1 |
| Tremolizzo, L | 3 |
| Carboni, G | 1 |
| Ruzicka, WB | 2 |
| Mitchell, CP | 1 |
| Sugaya, I | 1 |
| Sharma, R | 1 |
| Tracy, KA | 2 |
| Sommerville, KW | 1 |
| Hosák, L | 1 |
| Libiger, J | 1 |
| Jagadheesan, K | 1 |
| Duggal, H | 1 |
| Gupta, S | 1 |
| Basu, S | 1 |
| Ranjan, S | 1 |
| Sandil, R | 1 |
| Akhtar, S | 1 |
| Nizamie, SH | 1 |
| Chen, KC | 1 |
| Yang, YK | 1 |
| Chen, PS | 1 |
| Yeh, TL | 1 |
| Yang, MJ | 1 |
| Isaac, MB | 1 |
| Isaac, MT | 1 |
| Kravetz, JD | 1 |
| Federman, DG | 1 |
| Winterer, G | 2 |
| Stahl, SM | 2 |
| Grady, MM | 1 |
| Boylan, LS | 1 |
| Labovitz, DL | 1 |
| Basan, A | 2 |
| Berigan, TR | 1 |
| Littrell, KH | 1 |
| Petty, RG | 1 |
| Hilligoss, NM | 1 |
| Kirshner, CD | 1 |
| Johnson, CG | 1 |
| Kochan, LD | 1 |
| Tremeau, F | 1 |
| Wynn, PS | 1 |
| Roy, B | 1 |
| Dinakar, H | 1 |
| Lopez, LM | 1 |
| Molloy, MS | 1 |
| Williams, NG | 1 |
| Coffey, G | 1 |
| Botts, S | 1 |
| Green, B | 1 |
| Kissling, W | 1 |
| Duggal, HS | 1 |
| Eilers, R | 1 |
| Jacquet, H | 1 |
| Demily, C | 1 |
| Houy, E | 1 |
| Hecketsweiler, B | 1 |
| Bou, J | 1 |
| Raux, G | 1 |
| Lerond, J | 1 |
| Allio, G | 1 |
| Haouzir, S | 1 |
| Tillaux, A | 1 |
| Bellegou, C | 1 |
| Fouldrin, G | 1 |
| Delamillieure, P | 1 |
| Ménard, JF | 1 |
| Dollfus, S | 1 |
| D'Amato, T | 1 |
| Petit, M | 1 |
| Thibaut, F | 1 |
| Frébourg, T | 1 |
| Campion, D | 1 |
| Josiassen, R | 1 |
| Bark, N | 1 |
| Salazar, DE | 1 |
| Mallikaarjun, S | 1 |
| Maloku, E | 1 |
| Begum, M | 1 |
| Doueiri, MS | 1 |
| Davis, J | 1 |
| Pinna, G | 1 |
| Rodriguez-Menendez, V | 1 |
| Stewart, JT | 1 |
| Koike, AK | 1 |
| Simmons, JE | 1 |
| Telles, S | 1 |
| Eggleston, C | 1 |
| Berle, JØ | 1 |
| Spigset, O | 1 |
| Hahn, CG | 1 |
| Koneru, R | 1 |
| Levinson, DF | 1 |
| Friedman, E | 1 |
| Chan, YC | 1 |
| Miller, KM | 1 |
| Shaheen, N | 1 |
| Votolato, NA | 1 |
| Hankins, MB | 1 |
| Wong, JO | 1 |
| Leung, SP | 1 |
| Mak, T | 1 |
| Ng, RM | 1 |
| Chan, KT | 1 |
| Hon-Kee Cheung, H | 1 |
| Choi, WK | 1 |
| Lai, J | 1 |
| Wai-Kiu Tsang, A | 1 |
| Kelly, DL | 1 |
| Conley, RR | 1 |
| Feldman, S | 1 |
| Yu, Y | 1 |
| McMahon, RP | 1 |
| Richardson, CM | 1 |
| Bhatti, MA | 1 |
| Zander, J | 1 |
| Reeve, E | 1 |
| Keown, P | 1 |
| McAllister-Williams, H | 1 |
| Young, A | 1 |
| Tsutsumi, Y | 1 |
| Chinnasamy, D | 1 |
| Rudd, R | 1 |
| Velakoulis, D | 1 |
| Cowan, C | 1 |
| Oakley, C | 1 |
| Gobbi, G | 1 |
| Gaudreau, PO | 1 |
| Leblanc, N | 1 |
| Rosen, C | 1 |
| Simonini, MV | 1 |
| Bowden, CL | 1 |
| Kilbourne, AM | 1 |
| Post, EP | 1 |
| Bauer, MS | 1 |
| Zeber, JE | 1 |
| Copeland, LA | 1 |
| Good, CB | 1 |
| Pincus, HA | 1 |
| Yoshimura, R | 1 |
| Shinkai, K | 1 |
| Ueda, N | 1 |
| Nakamura, J | 1 |
| Lam, MH | 1 |
| Fong, SY | 1 |
| Wing, YK | 1 |
| Chen, H | 1 |
| Kennedy, WK | 1 |
| Dorfman, JH | 1 |
| Fincham, JE | 1 |
| Reeves, J | 1 |
| Martin, BC | 1 |
| Sajatovic, M | 1 |
| Coconcea, N | 1 |
| Ignacio, RV | 1 |
| Blow, FC | 1 |
| Hays, RW | 1 |
| Cassidy, KA | 1 |
| Meyer, WJ | 3 |
| Nakamura, M | 1 |
| Salisbury, DF | 1 |
| Hirayasu, Y | 1 |
| Bouix, S | 1 |
| Pohl, KM | 1 |
| Yoshida, T | 1 |
| Koo, MS | 1 |
| Shenton, ME | 1 |
| McCarley, RW | 1 |
| Winter, HR | 1 |
| DeVane, CL | 1 |
| Figueroa, C | 1 |
| Ennis, DJ | 1 |
| Hamer-Maansson, JE | 1 |
| Davis, PC | 1 |
| Smith, MA | 1 |
| Zink, M | 1 |
| Englisch, S | 1 |
| Knopf, U | 1 |
| Kuwilsky, A | 1 |
| Dressing, H | 1 |
| Czobor, P | 1 |
| Tegeler, J | 1 |
| Wöller, W | 1 |
| Garbutt, JC | 1 |
| van Kammen, DP | 1 |
| Kausen, J | 1 |
| Zimmermann, P | 1 |
| Fünfgeld, EW | 1 |
| Klenke, D | 1 |
| Henkel, H | 1 |
| Ishizaki, T | 1 |
| Chiba, K | 1 |
| Saito, M | 1 |
| Kobayashi, K | 1 |
| Iizuka, R | 1 |
| Meldrum, B | 1 |
| Emrich, HM | 2 |
| Altmann, H | 1 |
| Dose, M | 2 |
| von Zerssen, D | 1 |
| Nair, NP | 1 |
| Lal, S | 1 |
| Schwartz, G | 1 |
| Thavundayil, JX | 1 |
| Lautin, A | 2 |
| Angrist, B | 2 |
| Stanley, M | 2 |
| Gershon, S | 2 |
| Heckl, K | 1 |
| Karobath, M | 1 |
| Puryear, LJ | 2 |
| Kunik, ME | 2 |
| Molinari, V | 1 |
| Workman, RH | 1 |
| Longo, LP | 1 |
| Salzman, C | 1 |
| Guthrie, SK | 1 |
| Stoysich, AM | 1 |
| Bader, G | 1 |
| Hilleman, DE | 1 |
| Finley, P | 1 |
| Warner, D | 1 |
| Ranjan, R | 1 |
| Kando, J | 1 |
| Frankenburg, FR | 1 |
| Volpicelli, SA | 1 |
| Puopolo, PR | 1 |
| Flood, JG | 1 |
| Vojvoda, D | 1 |
| Grimmell, K | 1 |
| Sernyak, M | 1 |
| Mazure, CM | 1 |
| Workman, R | 1 |
| Maes, M | 1 |
| Goossens, F | 1 |
| Scharpé, S | 1 |
| Calabrese, J | 1 |
| Desnyder, R | 1 |
| McDonald, WM | 1 |
| Nemeroff, CB | 1 |
| Chong, SA | 1 |
| Tan, CH | 1 |
| Lee, EL | 1 |
| Liow, PH | 1 |
| Moore, DP | 1 |
| Hellweg, R | 1 |
| Yassouridis, A | 1 |
| Theison, M | 1 |
| Levine, J | 2 |
| Allingham, B | 2 |
| Sanders, RD | 1 |
| Lehrer, DS | 1 |
| Mahendran, R | 1 |
| Dott, SG | 2 |
| Harris, A | 2 |
| Brown, A | 2 |
| O'Boyle, M | 2 |
| Rose, RM | 2 |
| Facciolà, G | 1 |
| Avenoso, A | 1 |
| Scordo, MG | 1 |
| Madia, AG | 1 |
| Ventimiglia, A | 1 |
| Perucca, E | 1 |
| Spina, E | 1 |
| Hesslinger, B | 1 |
| Normann, C | 1 |
| Langosch, JM | 1 |
| Klose, P | 1 |
| Berger, M | 1 |
| Walden, J | 1 |
| Ghani, SO | 1 |
| Ahmed, W | 1 |
| Marco, LA | 1 |
| Cagliero, E | 1 |
| Gray, C | 1 |
| Nasrallah, RA | 1 |
| Hayden, DL | 1 |
| Schoenfeld, DA | 1 |
| Goff, DC | 1 |
| Luchins, DJ | 1 |
| Klass, D | 1 |
| Hanrahan, P | 1 |
| Qayyum, M | 1 |
| Malan, R | 1 |
| Raskin-Davis, V | 1 |
| Fichtner, CG | 1 |
| Kane, SL | 1 |
| Constantiner, M | 1 |
| Staubus, AE | 1 |
| Meinecke, CD | 1 |
| Sedor, JR | 1 |
| Hermann, WM | 1 |
| Hafiz, NG | 1 |
| Hampton, D | 1 |
| Molloy, M | 1 |
| Narendran, R | 1 |
| Young, CM | 1 |
| Valenti, AM | 1 |
| Pristach, CA | 1 |
| Pato, MT | 1 |
| Grace, JJ | 1 |
| Pantelis, C | 1 |
| Adesanya, A | 1 |
| Hardy-Baylé, MC | 1 |
| Afaq, I | 1 |
| Riaz, J | 1 |
| Sedky, K | 1 |
| Chung, DJ | 1 |
| Vanina, Y | 1 |
| el-Mallakh, R | 1 |
| Lippmann, S | 1 |
| Meyer, JM | 1 |
| Nagao, T | 1 |
| Ohshimo, T | 1 |
| Mitsunobu, K | 1 |
| Sato, M | 1 |
| Otsuki, S | 1 |
| Koran, LM | 1 |
| van den Berg, CJ | 1 |
| Gibson, AC | 1 |
| Uehlinger, C | 1 |
| Barrelet, L | 1 |
| Touabi, M | 1 |
| Baumann, P | 1 |
| Karper, LP | 1 |
| Seibyl, JP | 1 |
| Krystal, JH | 1 |
| Koizumi, J | 1 |
| Moroji, T | 1 |
| Shiraishi, H | 1 |
| Hori, T | 1 |
| Baba, A | 1 |
| Kawai, N | 1 |
| Tada, K | 1 |
| Nasser, D | 1 |
| Thomas, B | 1 |
| Moriñigo, A | 1 |
| Martin, J | 1 |
| Gonzalez, S | 1 |
| Mateo, I | 1 |
| Raevskiĭ, KS | 1 |
| Aleksandrovskiĭ, IuA | 1 |
| Poiurovskiĭ, MV | 1 |
| Kharlamov, AN | 1 |
| Neznamov, GG | 1 |
| Monteleone, P | 3 |
| Zontini, G | 1 |
| Steardo, L | 3 |
| Maj, M | 2 |
| Iovino, M | 2 |
| Zapletálek, M | 1 |
| Hanus, H | 1 |
| Kindernayová, H | 1 |
| Schnetzler, JP | 1 |
| Préaubert, G | 1 |
| Schnetzler, F | 1 |
| Ariano, MG | 1 |
| Fiorenza, L | 1 |
| Ko, GN | 1 |
| Korpi, ER | 1 |
| Freed, WJ | 1 |
| Zalcman, SJ | 1 |
| Bigelow, LB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigation of the Effects of in Vivo Lithium Treatment on Gene Expression Levels Using Lymphoblastoid Cell Lines From Human Healthy Subjects[NCT01565759] | Phase 1 | 20 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | ||
| Nicotine Intake in Smokers With Schizophrenia[NCT00382915] | 276 participants (Actual) | Observational | 2006-10-31 | Completed | |||
| Effects of Risperidone and Olanzapine on Weight Gain, Physical Health, and Outcome in a Community Sample of Severity and Persistently Ill Patients[NCT00179062] | 300 participants (Actual) | Interventional | 2000-02-29 | Completed | |||
| Switching Antipsychotics: Abrupt Discontinuation Versus Overlap[NCT02640300] | Phase 4 | 33 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication[NCT02624167] | Phase 2 | 90 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Add-on Valproate in Late Life Schizophrenia[NCT00194025] | Phase 4 | 20 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility[NCT00308360] | Phase 4 | 46 participants | Interventional | 1999-09-30 | Completed | ||
| Prophylactic Use of Immediate Postpartum Sertraline to Prevent Postpartum Depression: A Double Blind Randomized Placebo Controlled Trial[NCT02235064] | 2 participants (Actual) | Interventional | 2014-07-31 | Terminated (stopped due to Low recruitment, completion of funding cycle) | |||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis[NCT00337350] | Phase 4 | 20 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033] | Phase 4 | 38 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The best and worst possible overall scores are 31 and 0 units on a scale, respectively. (NCT00194025)
Timeframe: Baseline to 12 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Valproate | 0.4 |
The best and worst possible GDS scores are 0 and 30 units on a scale, respectively. (NCT00194025)
Timeframe: Baseline to 12 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Valproate | -1.556 |
The best and worst possible overall scores are 0 and 28 units on a scale, respectively. (NCT00194025)
Timeframe: Baseline to 12 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Valproate | -2.105 |
The best and worst possible overall scores are 40 and 0 units on a scale, respectively. (NCT00194025)
Timeframe: Baseline to 12 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Valproate | -0.6 |
The best and worst possible GAS scores are 100 and 1 units on a scale, respectively. (NCT00194025)
Timeframe: Baseline to 12 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Valproate | 16.35 |
The best and worst possible MCS scores are 100 and 1 units on a scale, respectively. (NCT00194025)
Timeframe: Baseline to 12 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Valproate | 5.298 |
The best and worst possible PCS scores are 100 and 0 units on a scale, respectively. (NCT00194025)
Timeframe: Baseline to 12 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Valproate | 0.932 |
The best and worst possible overall PANSS scores are 30 and 210 units on a scale, respectively. (NCT00194025)
Timeframe: Baseline to 12 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Valproate | -17.45 |
(NCT00194025)
Timeframe: Baseline to 12 weeks
| Intervention | kilograms (Mean) |
|---|---|
| Valproate | 1.1 |
(NCT00194025)
Timeframe: Baseline to 12 weeks
| Intervention | ug/mL (Mean) |
|---|---|
| Valproate | 40.86 |
The Antidepressant Side-Effect Checklist (ASEC) was employed to detect any adverse reaction to treatment regimens (NCT02235064)
Timeframe: Discharge from hospital to 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 1 |
"Patients met with single psychiatrist (co-investigator), blinded to group assignment, who evaluated the patient using Edinburgh Postpartum Depression Screen, Hamilton Depression Rating Scale, Global Assessment of Functioning Scale, and clinical assessment~0 = No postpartum depression up to 12 weeks following discharge from hospital~1 = Postpartum depression up to 12 weeks following discharge from hospital" (NCT02235064)
Timeframe: Discharge from hospital to 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 5301 |
| Placebo | 4734 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 3033 |
| Placebo | 2750 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 5301 |
| Placebo | 3685 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
Acute insulin response to glucose (AIRG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. AIRG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. AIRG measures the acute(0-10 min) beta cell response to a glucose load calculated by the areas under the curve higher than basal insulin values. The AIRG was assessed as the incremental area under the curve (calculated by the trapezoid rule) from 0 to 10 min of the FSIVGTT. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | Units/mL per 10 minutes (Mean) |
|---|---|
| Rosiglitazone | -151 |
| Placebo | 19 |
Insulin Sensitivity (IS) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in IS between Baseline and week 8. SI was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SI represents the increase in net fractional glucose clearance rate per unit change in serum insulin concentration after the intravenous glucose load (microUnits/mL). (NCT00337350)
Timeframe: baseline, week 8
| Intervention | microUnits/mL (Mean) |
|---|---|
| Rosiglitazone | 3.2 |
| Placebo | 0.4 |
Glucose utilization (SG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. SG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SG represents the net fractional glucose clearance rate because of the increase in glucose independent of any increase in circulating insulin concentrations above baseline. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Rosiglitazone | .002 |
| Placebo | -0.01 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.52 |
| Placebo | 0.03 |
A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Aripiprazole | 0.003 |
| Placebo | -0.005 |
A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Aripiprazole | 0.6 |
| Placebo | 0.65 |
A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -15.3 |
| Placebo | 5.6 |
(NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -5.9 |
| Placebo | -7.3 |
A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg (Mean) |
|---|---|
| Aripiprazole | -1.5 |
| Placebo | 0.3 |
28 reviews available for valproic acid and Schizophrenia
| Article | Year |
|---|---|
[Recommendations about the Use of Psychotropic Medications during the COVID-19 Pandemic].
Topics: Antiviral Agents; Benzodiazepines; Betacoronavirus; Bipolar Disorder; Body Temperature Regulation; B | 2020 |
Valproate for Schizophrenia.
Topics: Antimanic Agents; Humans; Schizophrenia; Valproic Acid | 2018 |
Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Epilepsy; Hum | 2019 |
Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis Study.
Topics: Anticonvulsants; Antipsychotic Agents; Drug Synergism; Drug Therapy, Combination; Humans; Psychotic | 2016 |
Valproate for schizophrenia.
Topics: Antimanic Agents; Antipsychotic Agents; Humans; Randomized Controlled Trials as Topic; Schizophrenia | 2016 |
Valproate for schizophrenia.
Topics: Antimanic Agents; Antipsychotic Agents; Humans; Randomized Controlled Trials as Topic; Schizophrenia | 2008 |
Adding lithium or anticonvulsants to antipsychotics for the treatment of schizophrenia: useful strategy or exercise in futility?
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Delayed-Action Preparations; Drug Therapy, | 2009 |
[The optimal combination of ECT with pharmacotherapy].
Topics: Affect; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tric | 2011 |
Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors.
Topics: Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, | 2013 |
Antiepileptic drugs in schizophrenia: a review.
Topics: Anticonvulsants; Antipsychotic Agents; Carbamazepine; Drug Resistance; Humans; Lamotrigine; Receptor | 2002 |
A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
Topics: Acetates; Amines; Anticonvulsants; Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Cycloh | 2004 |
Valproate for schizophrenia.
Topics: Antimanic Agents; Antipsychotic Agents; Humans; Randomized Controlled Trials as Topic; Schizophrenia | 2004 |
Epigenetic downregulation of GABAergic function in schizophrenia: potential for pharmacological intervention?
Topics: Animals; Brain; Cell Adhesion Molecules, Neuronal; Epigenesis, Genetic; Extracellular Matrix Protein | 2003 |
Schizophrenia and valproate.
Topics: Affect; Aggression; Antimanic Agents; Clinical Trials as Topic; Humans; Schizophrenia; Schizophrenic | 2003 |
Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials.
Topics: Anticonvulsants; Antipsychotic Agents; Drug Synergism; Drug Therapy, Combination; Humans; Randomized | 2004 |
[Are mood stabilizers beneficial in the treatment of schizophrenia?].
Topics: Antimanic Agents; Antipsychotic Agents; Carbamazepine; Drug Interactions; Drug Therapy, Combination; | 2005 |
[Necessity of novel single-antipsychotic-agent therapies for acute phase of schizophrenia].
Topics: Acute-Phase Reaction; Antipsychotic Agents; Benzodiazepines; Dopamine; Dopamine Antagonists; Dosage | 2006 |
Epigenetic targets in GABAergic neurons to treat schizophrenia.
Topics: Animals; Cerebral Cortex; Epigenesis, Genetic; GABA Agents; gamma-Aminobutyric Acid; Humans; Molecul | 2006 |
Spectrum of effectiveness of valproate in neuropsychiatry.
Topics: Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug | 2007 |
ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Bipolar Disorder; Breast Feed | 2008 |
The interaction between GABA and dopamine: implications for schizophrenia.
Topics: Animals; Antipsychotic Agents; Baclofen; Brain Chemistry; Catalepsy; Dopamine; gamma-Aminobutyric Ac | 1983 |
Pharmacology of GABA.
Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep | 1982 |
The diagnosis and treatment of mania in the elderly.
Topics: Age of Onset; Aged; Anticonvulsants; Bipolar Disorder; Carbamazepine; Diagnosis, Differential; Dose- | 1996 |
Neuropsychiatric aspects of Sydenham's chorea: a comprehensive review.
Topics: Adult; Autoimmune Diseases; Chorea; Comorbidity; Haloperidol; Humans; Mental Disorders; Obsessive-Co | 1996 |
Critical review of GABA-ergic drugs in the treatment of schizophrenia.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dopamine; GABA | 1999 |
Neuroleptic malignant syndrome and severe thrombocytopenia: case report and literature review.
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Haloperidol; Humans; Male; Neuroleptic Malig | 2000 |
Valproate and the symptomatic treatment of schizophrenia spectrum patients.
Topics: Clinical Trials as Topic; GABA Agents; Humans; Schizophrenia; Valproic Acid | 2000 |
[A valproic acid-diazepam combination as an alternative to neuroleptic treatment].
Topics: Adult; Aged; Aged, 80 and over; Bipolar Disorder; Diazepam; Drug Combinations; Female; Humans; Male; | 1988 |
28 trials available for valproic acid and Schizophrenia
| Article | Year |
|---|---|
Randomized controlled trial of adjunctive Valproate for cognitive remediation in early course schizophrenia.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Cognitive Dysfunction; Double-Blind Metho | 2019 |
Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate.
Topics: Adult; Anthropometry; Antipsychotic Agents; Body Mass Index; Body Weight; C-Reactive Protein; Clozap | 2018 |
Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Double-Blind M | 2009 |
A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Femal | 2009 |
Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Drug Therapy, Combination; Female; Humans; Japan; Mal | 2009 |
A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; GABA Agents; Hum | 2011 |
Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Double-Blind Metho | 2003 |
Acute antimanic efficacy and safety of intravenous valproate loading therapy: an open-label study.
Topics: Administration, Oral; Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Diagnostic and Statisti | 2003 |
Valproate for hostility in schizophrenia patients.
Topics: Adult; Anticonvulsants; Benzodiazepines; Female; Hostility; Humans; Male; Olanzapine; Schizophrenia; | 2004 |
Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Therapy, Combination; H | 2004 |
A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia.
Topics: Adult; Brief Psychiatric Rating Scale; Chemistry, Pharmaceutical; Delayed-Action Preparations; Femal | 2004 |
Hyperprolinemia is a risk factor for schizoaffective disorder.
Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Case-Control Studies; Chromosomes, | 2005 |
Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Blood Platelets; Enzyme Activation; Female; GTP-Binding P | 2005 |
Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Area Under Curve; Bipolar Disorder; Cohort Studies; D | 2007 |
Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility.
Topics: Adult; Aggression; Anticonvulsants; Antipsychotic Agents; Diarrhea; Drug Therapy, Combination; Femal | 2007 |
Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report.
Topics: Adolescent; Adult; Analgesics; Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as | 1983 |
Sodium valproate in schizophrenia: some biochemical correlates.
Topics: Adult; Clinical Trials as Topic; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Male; Methoxyhy | 1980 |
Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate.
Topics: Adult; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Comb | 1994 |
Combined treatment of schizophrenic psychoses with haloperidol and valproate.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Biperiden; Brief Psychiatric Rating Scale; Chlo | 1998 |
Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Clozapine; Drug Interactions; Drug Therapy, Combinatio | 1999 |
Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Drug Interactions; Drug Therapy, Combi | 1999 |
Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Comb | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Drug Therapy, Combination; Female; Haloperidol; Hospi | 2001 |
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.
Topics: Adult; Affective Disorders, Psychotic; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; | 2001 |
Growth hormone response to sodium valproate in chronic schizophrenia.
Topics: Adult; Brain; Chronic Disease; Double-Blind Method; gamma-Aminobutyric Acid; Growth Hormone; Humans; | 1986 |
Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Humans; Male; Middle Aged; Prolactin; Psychiatric Status Rati | 1988 |
Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenic patients.
Topics: Adult; Amino Acids; Behavior; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; M | 1985 |
132 other studies available for valproic acid and Schizophrenia
| Article | Year |
|---|---|
Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia.
Topics: Adult; Alleles; Anticonvulsants; Asian People; China; Chromatography, High Pressure Liquid; Cytochro | 2021 |
Quetiapine-associated thrombocytopenic purpura in a young man with a first episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Humans; Male; Purpura, Thrombocytopenic; Quetiapine Fumarat | 2023 |
Four cases of myocarditis in US hospitals possibly associated with clozapine poor metabolism and a comparison with prior published cases.
Topics: Antipsychotic Agents; Clozapine; Hospitals; Humans; Male; Myocarditis; Obesity; Schizophrenia; Valpr | 2022 |
Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: Does UGT polymorphism affect these drug interactions?
Topics: Albumins; Antipsychotic Agents; Chromatography, Liquid; Clozapine; Cytochrome P-450 CYP2C19; Drug In | 2022 |
Real-world effectiveness of mood stabilizer use in schizophrenia.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Carbamazepine; Female; Humans; Lamotrigine; | 2023 |
Effect of smoking habits and concomitant valproic acid use on relapse in patients with treatment-resistant schizophrenia receiving clozapine: A 1-year retrospective cohort study.
Topics: Antipsychotic Agents; Clozapine; Habits; Humans; Retrospective Studies; Schizophrenia; Schizophrenia | 2023 |
Clozapine-induced myocarditis during co-administration of valproate: A case report.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Humans; Male; Myocarditis; Schizophrenia | 2019 |
A Retrospective Analysis of Steady-State Olanzapine Concentrations in Chinese Patients Using Therapeutic Drug Monitoring: Effects of Valproate and Other Factors.
Topics: Adolescent; Adult; Antipsychotic Agents; Asian People; Drug Monitoring; Female; Humans; Male; Middle | 2020 |
Activation of Astroglial Connexin is Involved in Concentration-Dependent Double-Edged Sword Clinical Action of Clozapine.
Topics: Antipsychotic Agents; Astrocytes; Cell Membrane; Clozapine; Connexin 43; Glutamic Acid; Humans; Myoc | 2020 |
Valproate for schizophrenia: ambrosia?
Topics: Ambrosia; Antimanic Agents; Antipsychotic Agents; Humans; Schizophrenia; Valproic Acid | 2021 |
The investigation of the in vivo cytogenetic effects of psychotropic drugs in human lymphocyte cultures.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Cell Proliferation; Cells, Cultured; Cytogenetic | 2020 |
Association between valproate treatment for acute phase schizophrenia and risk of new onset hypothyroidism.
Topics: Antimanic Agents; Humans; Hypothyroidism; Retrospective Studies; Schizophrenia; Valproic Acid | 2021 |
Decreased NOX2 expression in the brain of patients with bipolar disorder: association with valproic acid prescription and substance abuse.
Topics: Adult; Bipolar Disorder; Brain; Female; Gyrus Cinguli; Humans; Male; Microglia; Middle Aged; NADPH O | 2017 |
Primary cilia formation is diminished in schizophrenia and bipolar disorder: A possible marker for these psychiatric diseases.
Topics: Adenylyl Cyclases; Adult; Bipolar Disorder; Cilia; Enzyme Inhibitors; Female; Humans; Male; Neural S | 2018 |
Associations between use of mood stabilizers and risk of cataract: A population-based nested case-control study.
Topics: Adult; Aged; Antimanic Agents; Bipolar Disorder; Carbamazepine; Case-Control Studies; Cataract; Data | 2018 |
Clozapine toxicity in a CYP2D6 poor metaboliser: Additive effects of haloperidol and valproate on clozapine metabolism.
Topics: Adult; Antipsychotic Agents; Clozapine; Cytochrome P-450 CYP2D6; Drug Synergism; Haloperidol; Humans | 2018 |
Severe hair loss associated with psychotropic drugs in psychiatric inpatients-Data from an observational pharmacovigilance program in German-speaking countries.
Topics: Adult; Alopecia; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Austria; Bipolar Dis | 2018 |
Association between electroencephalogram changes and plasma clozapine levels in clozapine-treated patients.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Clozapine; Drug Monitoring; Electroencephalography; F | 2019 |
Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate.
Topics: Antiprotozoal Agents; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; | 2014 |
The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Case-Control Studies; Diagnostic and Statistical Manua | 2014 |
Successful treatment of catatonia in a young man with schizophrenia and progressive diffuse cerebral atrophy.
Topics: Adolescent; Amantadine; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Atrophy; Catato | 2014 |
Valproate reverts zinc and potassium imbalance in schizophrenia-derived reprogrammed cells.
Topics: Antipsychotic Agents; Cell Line; Clozapine; Drug Resistance; Embryonic Stem Cells; Humans; Induced P | 2014 |
Off-label use of sodium valproate for schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Hospitals, Psychiatric; Humans; Male; Middle Age | 2014 |
Increased platelet intracellular calcium ion concentration is specific to bipolar disorder.
Topics: Adult; Antipsychotic Agents; Biomarkers; Bipolar Disorder; Blood Platelets; Calcium; Case-Control St | 2014 |
Clozapine-related pericarditis during titration phase in a patient with resistant schizophrenia and concomitant valproate treatment: a case report.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Drug Therapy, Combination; Humans; Indometh | 2014 |
[Use of valproic acid in long stay units of psychiatry].
Topics: Adult; Aged; Antimanic Agents; Bipolar Disorder; Cross-Sectional Studies; Epilepsy; Female; Humans; | 2015 |
Optimization of psychopharmacotherapy for schizophrenia in a male, locked, non-acute unit serving for persistently ill patients over one year.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Humans; Inpatients; M | 2015 |
Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Prescriptions; Drug Thera | 2015 |
Enhanced conversion of induced neuronal cells (iN cells) from human fibroblasts: Utility in uncovering cellular deficits in mental illness-associated chromosomal abnormalities.
Topics: Adolescent; Adult; Azacitidine; Cell Culture Techniques; Cell Differentiation; Chromosome Aberration | 2015 |
Valproic acid (VPA) reduces sensorimotor gating deficits and HDAC2 overexpression in the MAM animal model of schizophrenia.
Topics: Acetylation; Animals; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; Histo | 2015 |
Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Clozapine; Cohort Studies; Drug Therapy, Combination; | 2015 |
Editorial.
Topics: Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Humans; Psych | 2016 |
Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Blood Glucose; Body Mass Index; Cross-Sectional Studi | 2016 |
Ibuprofen May Increase Pharmacological Action of Valproate by Displacing It From Plasma Proteins: A Case Report.
Topics: Antipsychotic Agents; Blood Proteins; Clozapine; Drug Synergism; Drug Therapy, Combination; Humans; | 2016 |
The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; | 2008 |
Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling.
Topics: Animals; Antipsychotic Agents; Cell Adhesion Molecules, Neuronal; Chromatin Assembly and Disassembly | 2009 |
Extreme elevation of creatinine phosphokinase levels in neuroleptic malignant syndrome associated with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, D | 2009 |
Expression of mitochondrial complex I subunit gene NDUFV2 in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Antimanic Agents; Bipolar Disorder; Cell Line, Transformed; Female; | 2009 |
Histone deacetylase inhibitors and candidate gene expression: An in vivo and in vitro approach to studying chromatin remodeling in a clinical population.
Topics: Acetylation; Adult; Bipolar Disorder; Blotting, Western; Cell Culture Techniques; Enzyme Inhibitors; | 2009 |
Unrecognized valproic acid intoxication.
Topics: Adult; Anticonvulsants; Electroencephalography; Humans; Male; Schizophrenia; Suicide, Attempted; Val | 2009 |
Staff and patient views of the reasons for aggressive incidents: a prospective, incident-based study.
Topics: Adult; Aggression; Antimanic Agents; Attitude of Health Personnel; Attitude to Health; Cohort Studie | 2009 |
L-methionine decreases dendritic spine density in mouse frontal cortex.
Topics: Animals; Anticonvulsants; Cell Adhesion Molecules, Neuronal; Cell Differentiation; Cell Shape; Dendr | 2010 |
Clinical correlates of low serum carnitine levels in hospitalized psychiatric patients.
Topics: Adult; Aged; Antimanic Agents; Carnitine; Female; Humans; Inpatients; Male; Mental Disorders; Middle | 2011 |
Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness.
Topics: Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Bipolar Disorder; Carbamazepine; Cotinine; Cy | 2010 |
Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients.
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dr | 2011 |
Further characterization of the predictive validity of the Brattleboro rat model for antipsychotic efficacy.
Topics: Animals; Antipsychotic Agents; Chlorpromazine; Diazepam; Disease Models, Animal; Female; Imipramine; | 2011 |
Evidence for association of hyperprolinemia with schizophrenia and a measure of clinical outcome.
Topics: 1-Pyrroline-5-Carboxylate Dehydrogenase; Adolescent; Adult; Aged; Amino Acid Metabolism, Inborn Erro | 2011 |
Generalised spike-and-slow-wave complexes without seizures in schizophrenia.
Topics: Adolescent; Anticonvulsants; Electroencephalography; Humans; Male; Schizophrenia; Valproic Acid | 2011 |
Carnitine supplementation for valproate-related hyperammonemia to maintain therapeutic valproate level.
Topics: Adult; Anticonvulsants; Antisocial Personality Disorder; Carnitine; Humans; Hyperammonemia; Male; Sc | 2011 |
Altered oxygen metabolism associated to neurogenesis of induced pluripotent stem cells derived from a schizophrenic patient.
Topics: Cells, Cultured; Female; Fibroblasts; Gene Expression; Humans; Induced Pluripotent Stem Cells; Middl | 2012 |
Valproate and high dosage of zotepine induced acute delirium: a case report.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Delirium; Dibenzothiepins; Dose-Response Relationship | 2012 |
Effects of adjunct valproic acid on clinical symptoms and saccadic eye movements in schizophrenia.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Case-Control Studies; Cognition; Dose-Response Relati | 2011 |
Persistent febrile illness with multisystem organ failure associated with clozapine.
Topics: Abdominal Pain; Adult; Antipsychotic Agents; Clozapine; Combined Modality Therapy; Diagnostic Errors | 2012 |
Valproic acid augmentation in clozapine-associated hand-washing compulsion.
Topics: Anticonvulsants; Antipsychotic Agents; Clozapine; Compulsive Behavior; Hand Disinfection; Humans; Ma | 2012 |
Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Antipsychotic Agents; Area Under Curve; Body | 2012 |
Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
Topics: Administration, Oral; Adult; Anticonvulsants; Antipsychotic Agents; Caffeine; Case-Control Studies; | 2013 |
Prophylactic valproic acid treatment prevents schizophrenia-related behaviour in Disc1-L100P mutant mice.
Topics: Acute-Phase Proteins; Animals; Antimanic Agents; Behavior, Animal; Crosses, Genetic; Gene Deletion; | 2012 |
Atypical neuroleptic malignant syndrome in H1N1 pneumonia.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Creatine Kinase; Haloperidol; Humans; Influ | 2013 |
An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability.
Topics: Acetylation; Animals; Cell Adhesion Molecules, Neuronal; CpG Islands; Disease Models, Animal; Diseas | 2002 |
Two case studies of hypothermia induced by an increased dosage of zotepine in a combination therapy.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Diazepam; Diben | 2003 |
Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
Topics: Benzodiazepines; Brief Psychiatric Rating Scale; Drug Therapy, Combination; Humans; Male; Olanzapine | 2003 |
Valproic acid-induced eosinophilic pleural effusion.
Topics: Adult; Anti-Bacterial Agents; Antimanic Agents; Ceftazidime; Chest Pain; Cough; Drainage; Drug Thera | 2003 |
Valproate and GABAergic system effects.
Topics: Brain; gamma-Aminobutyric Acid; Humans; Schizophrenia; Valproic Acid | 2003 |
Unbalanced statistical analysis of combined divalproex and antipsychotic therapy for schizophrenia.
Topics: Antipsychotic Agents; Data Interpretation, Statistical; Drug Therapy, Combination; Humans; Randomize | 2004 |
Possible role of divalproex sodium in sedation induced by antipsychotic medications.
Topics: Antimanic Agents; Antipsychotic Agents; Drug Interactions; Humans; Schizophrenia; Sleep Wake Disorde | 2004 |
Valproic acid induces manifestations of simultaneous dopamine enhancement and reduction in schizophrenia.
Topics: Adult; Benztropine; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interacti | 2004 |
Dosing differences between valproic acid concentrate and divalproex sodium: a case report.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Biological Availability; Clozapine; Delayed-Actio | 2004 |
Key developments in psychiatry.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cognitive Behavioral Therapy; Dementia; Hu | 2004 |
Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels.
Topics: Affect; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Therapy, Combin | 2004 |
Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis?
Topics: Acute Disease; Anticonvulsants; Cognition Disorders; Fructose; Humans; Psychiatric Status Rating Sca | 2004 |
Antihostility effects of adjunctive divalproex.
Topics: Anticonvulsants; Antipsychotic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hostilit | 2004 |
Pharmacokinetics of aripiprazole and concomitant lithium and valproate.
Topics: Adult; Aripiprazole; Drug Therapy, Combination; Humans; Lithium; Male; Middle Aged; Piperazines; Psy | 2005 |
In psychosis, cortical interneurons overexpress DNA-methyltransferase 1.
Topics: Adult; Aged; Antipsychotic Agents; Biomarkers; Cell Adhesion Molecules, Neuronal; Cerebral Cortex; D | 2005 |
Clozapine-induced stuttering, facial tics and myoclonic seizures: a case report.
Topics: Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epilep | 2005 |
Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice.
Topics: Aggression; Animals; Anticonvulsants; Behavior, Animal; Benzodiazepines; Blotting, Western; Cell Adh | 2005 |
Treatment of valproate-induced hyperammonemia.
Topics: Aged; Antimanic Agents; Humans; Hyperammonemia; Male; Schizophrenia; Treatment Outcome; Valproic Aci | 2005 |
Adjunctive valproic acid for delirium and/or agitation on a consultation-liaison service: a report of six cases.
Topics: Alcohol Withdrawal Delirium; Alcoholism; Anticonvulsants; Delirium; Fever; Humans; Injections, Intra | 2005 |
Worsening of psychotic symptoms in schizophrenia with addition of lamotrigine: a case report.
Topics: Adult; Antipsychotic Agents; Brain; Clozapine; Drug Therapy, Combination; Female; Humans; Lamotrigin | 2005 |
Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antipsychotic Agents; China; Chromatography, High Pressure | 2006 |
Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia.
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Anxiety; Blood Glucose; Brief Psychi | 2006 |
Clozapine-induced pericarditis, pericardial tamponade, polyserositis, and rash.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Cardiac Tamponade; Clozapine; Drug Eruptions; Drug The | 2005 |
A case of pancytopenia.
Topics: Adult; Anticonvulsants; Folic Acid; Humans; Male; Pancytopenia; Schizophrenia; Schizophrenic Psychol | 2006 |
A case of schizophrenia with complete agenesis of the corpus callosum.
Topics: Adult; Agenesis of Corpus Callosum; Antidepressive Agents; Antipsychotic Agents; Cognition Disorders | 2006 |
Leukopenia and neutropenia induced by quetiapine.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Dibenzothiazepines; Drug Resistance; Female; Humans; | 2007 |
Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis.
Topics: Adult; Aggression; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Case-Control Studies; Dr | 2006 |
Valproic acid and chromatin remodeling in schizophrenia and bipolar disorder: preliminary results from a clinical population.
Topics: Adult; Antipsychotic Agents; Blotting, Western; Chromatin Assembly and Disassembly; Diagnostic and S | 2006 |
Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Cardiovascular Diseases; Drug Monitori | 2007 |
Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Drug Interactions; Female; Homovanillic Acid; Humans; | 2007 |
Sexual disinhibition in schizophrenia possibly induced by risperidone and quetiapine.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Clonazepam; Dibenzothiazepines; Female; GABA Modulato | 2007 |
The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
Topics: Adult; Affect; Algorithms; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Chemotherapy, Adju | 2007 |
Adjunct extended-release valproate semisodium in late life schizophrenia.
Topics: Adjuvants, Pharmaceutic; Aged; Antimanic Agents; Antipsychotic Agents; Female; Geriatric Psychiatry; | 2008 |
Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Algorithms; Antimanic Agents; Antipsychotic Agent | 2007 |
Augmentation of clozapine with valproic Acid for clozapine-induced obsessive-compulsive symptoms.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Humans; Male; O | 2007 |
[Epigenetic model in the pharmacologic modulation of vulnerability to schizophrenia].
Topics: Anticonvulsants; Brain; Cell Adhesion Molecules, Neuronal; Down-Regulation; Epigenesis, Genetic; Ext | 2007 |
[Therapeutic measures in tardive dyskinesia].
Topics: Age Factors; Amantadine; Antipsychotic Agents; Baclofen; Benzodiazepines; Bromocriptine; Deanol; Dih | 1983 |
Effects of a GABA-mimetic drug (sodium valproate) on visually evoked potentials in chronic schizophrenics.
Topics: Adult; Brain; Brief Psychiatric Rating Scale; Chronic Disease; Clozapine; Dibenzazepines; Drug Thera | 1984 |
The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Drug Interactions; Electroencephalography; Female; Half | 1984 |
Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies.
Topics: Adult; Baclofen; Chronic Disease; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Halop | 1980 |
Psychiatric manifestations of temporal lobe epilepsy in older adults.
Topics: Aged; Dementia; Depressive Disorder; Diagnosis, Differential; Electroencephalography; Epilepsy, Temp | 1995 |
Valproic acid effects on serum concentrations of clozapine and norclozapine.
Topics: Clozapine; Depression, Chemical; Drug Therapy, Combination; Humans; Schizophrenia; Seizures; Valproi | 1995 |
Hypothesized interaction between valproic acid and warfarin.
Topics: Aged; Blood Coagulation Tests; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug | 1995 |
Potential impact of valproic acid therapy on clozapine disposition.
Topics: Adult; Clozapine; Drug Interactions; Humans; Male; Middle Aged; Pilot Projects; Schizophrenia; Valpr | 1994 |
Valproic acid treatment of clozapine-induced myoclonus.
Topics: Adult; Clozapine; Drug Administration Schedule; Female; Humans; Myoclonus; Receptors, Serotonin; Sch | 1994 |
Monozygotic twins concordant for response to clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Diseases in Twins; Drug Therapy, Combination; Humans; Male; | 1996 |
Tolerability of divalproex sodium in elderly psychiatric patients with mixed diagnoses.
Topics: Aged; Anticonvulsants; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Tolerance; Female; H | 1995 |
Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs.
Topics: Affect; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Depressive | 1995 |
[Current knowledge on epilepsy, schizophrenia and spastic conditions. Neuro-Forum, Dresden, 5 April 1997].
Topics: Anticonvulsants; Carbamazepine; Chronic Disease; Epilepsies, Partial; Epilepsy; Humans; Remission In | 1997 |
[Current knowledge on epilepsy, schizophrenia and spastic conditions. Neuro-Forum, Dresden, 5 April 1997].
Topics: Anticonvulsants; Carbamazepine; Chronic Disease; Epilepsies, Partial; Epilepsy; Humans; Remission In | 1997 |
Augmentation of risperidone with valproic acid.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Drug Administration Schedule; Drug Therapy, Co | 1998 |
Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug Utilizatio | 1998 |
Edema associated with addition of risperidone to valproate treatment.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Dru | 1998 |
Obsessive-compulsive symptoms with risperidone.
Topics: Antipsychotic Agents; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Fluox | 1999 |
Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998.
Topics: Acetates; Adult; Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Cyc | 2000 |
Computerized monitoring of valproate and physician responsiveness to laboratory studies as a quality indicator.
Topics: Adult; Antimanic Agents; Biomarkers; Drug Monitoring; Drug Therapy, Computer-Assisted; Guideline Adh | 2000 |
High-flux hemodialysis without hemoperfusion is effective in acute valproic acid overdose.
Topics: Acidosis, Lactic; Adult; Algorithms; Anticonvulsants; Drug Overdose; Female; Half-Life; Hemodynamics | 2000 |
Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine.
Topics: Adult; Agranulocytosis; Anticonvulsants; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; | 2001 |
[Manic syndrome: diagnostic trends and principles of treatment].
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Chl | 1998 |
Divalproex as a calmative adjunct for aggressive schizophrenic patients.
Topics: Adult; Aggression; Antipsychotic Agents; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; | 2002 |
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Dia | 2002 |
Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor.
Topics: Adult; Chronic Disease; Cyclic AMP; Cyclic GMP; Cyproheptadine; Dyskinesia, Drug-Induced; Female; Ho | 1979 |
gamma-Aminobutyric-acid deficiency in schizophrenia.
Topics: Aminobutyrates; gamma-Aminobutyric Acid; Humans; Schizophrenia; Valerates; Valproic Acid | 1976 |
Gabergic compounds and schizophrenia.
Topics: Baclofen; gamma-Aminobutyric Acid; Humans; Schizophrenia; Valproic Acid | 1976 |
Sodium valproate and tardive dyskinesia.
Topics: Adult; Aged; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Schiz | 1978 |
Extrapyramidal syndrome with sodium valproate.
Topics: Basal Ganglia Diseases; Humans; Male; Middle Aged; Schizophrenia; Valproic Acid | 1979 |
Alopecia and mood stabilizers: two case reports.
Topics: Adult; Alopecia; Carbamazepine; Clorazepate Dipotassium; Depressive Disorder; Female; Fluvoxamine; H | 1992 |
Valproate management of psychosis in a patient with carbamazepine-induced hyponatremia.
Topics: Carbamazepine; Chronic Disease; Drinking; Drug Therapy, Combination; Humans; Hyponatremia; Male; Mid | 1992 |
Effects of long-term anticonvulsant therapy on copper, zinc, and magnesium in hair and serum of epileptics.
Topics: Adult; Anticonvulsants; Carbamazepine; Copper; Drug Therapy, Combination; Epilepsy, Generalized; Fem | 1992 |
Anticonvulsant treatment of psychoses.
Topics: Adult; Chronic Disease; Female; Humans; Male; Neurocognitive Disorders; Psychotic Disorders; Schizop | 1990 |
Treatment of resistant schizophrenia with valproate and neuroleptic drugs.
Topics: Adult; Antipsychotic Agents; Combined Modality Therapy; Drug Therapy, Combination; Electroconvulsive | 1989 |
[Anxiolytic action of sodium valproate (possible role of gamma-aminobutyric acid in affective disorders)].
Topics: Adult; Animals; Anti-Anxiety Agents; Anxiety; Brain; Cats; Female; gamma-Aminobutyric Acid; Humans; | 1985 |
Failure of the GABAergic drug, sodium valproate, to reduce basal plasma prolactin secretion in chronic schizophrenia.
Topics: Adult; Chronic Disease; Female; gamma-Aminobutyric Acid; Humans; Hypothalamo-Hypophyseal System; Mid | 1985 |
[Personal experience with the prophylactic effect of dipropylacetamide].
Topics: Adult; Bipolar Disorder; Depressive Disorder; Female; Humans; Male; Middle Aged; Psychotic Disorders | 1988 |